Skip to content
Lisata Therapeutics Lisata Therapeutics
Lisata Therapeutics Lisata Therapeutics
  • Careers
  • Contact Us
  • Policies
Active Clinical Trials
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Pancreatic Cancer & Advanced Solid TumorsLSTA1
    • Solid Tumors Tumor-Penetrating Nanocomplex (TPN) Platform™
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) LSTA201
    • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CendR Platform™ – Targeted penetration technology to enhance drug delivery to advanced solid tumors
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financials & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management Team
      • Board of Directors
    • Historical Information
      • Historical Press Releases
      • Historical SEC Filings
    • Investor Resources
      • Stockholder Information
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Policies & Disclosures
  • Patients & Families
    • Overview
    • Metastatic Pancreatic Cancer Symptoms & Treatment
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia and Buerger’s Disease Symptoms & Treatment
Home / Research & Technology / Publications / Agency Meetings with the US Food and Drug Administration

Agency Meetings with the US Food and Drug Administration

Sietsema W, Wekselman K. (2015.) Regulatory Focus. Regulatory Affairs Professionals Society.

Learn More
Lisata Therapeutics Lisata Therapeutics
Lisata Therapeutics Lisata Therapeutics
Active Clinical Trials
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Pancreatic Cancer & Advanced Solid Tumors LSTA1
    • Solid Tumors Tumor-Penetrating Nanocomplex (TPN) Platform™
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) LSTA201
    • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CendR Platform™ – Targeted penetration technology to enhance drug delivery to advanced solid tumors
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
    • Financials & Filings
    • Stock Information
    • Corporate Governance
    • Historical Information
    • Investor Resources
  • Patients & Families
    • Overview
    • Metastatic Pancreatic Cancer Symptoms & Treatment
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia and Buerger’s Disease Symptoms & Treatment
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Floor, Basking Ridge, NJ 07920|Telephone 908.842.0100

© Lisata Therapeutics, 2023. All Rights Reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Floor, Basking Ridge, NJ 07920|Telephone 908.842.0100